Lixosicone clinical trials
Also written AEF0117.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses lixosicone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Aelis Farma (7)
Studies
Open first, then newest update. How each study uses lixosicone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Drug-Drug Interaction Between THC and AEF0117WithdrawnPhase 1Aelis FarmaNCT06395688Written as 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one
- The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy VolunteersTerminatedPhase 1Aelis FarmaNCT05451017Written as 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition
- Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)CompletedPhase 2Aelis FarmaNCT05322941Written as AEF0117
- Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male SubjectsCompletedPhase 1Aelis FarmaNCT05554926Written as AEF0117
- Effect of AEF0117 on Subjective Effects of Cannabis in CUD SubjectsCompletedPhase 2Aelis FarmaNCT03717272Written as AEF0117
- Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117CompletedPhase 1Aelis FarmaNCT03443895Written as AEF0117 oral capsule
- Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117CompletedPhase 1Aelis FarmaNCT03325595Written as AEF0117
Codes
What other systems call lixosicone · ClinicalTrials.gg INT015886
- UNII (FDA) 9LG9CT78SVLIXOSICONEOne source FDA
- NCI Thesaurus C216040LixosiconeOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9LG9CT78SV | LIXOSICONE | One source FDA |
| NCI Thesaurus | C216040 | Lixosicone | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.